| Literature DB >> 36188002 |
Yu-Ling Han1,2, Xu-Hui Wen1,2, Wen Zhao1, Xi-Shan Cao1, Jian-Xun Wen3, Jun-Rui Wang1, Zhi-De Hu1, Wen-Qi Zheng1,2.
Abstract
Carbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-hvKP), a type of Klebsiella pneumoniae (KP) that exhibits hypervirulence and carbapenem resistance phenotypes, can cause severe infections, both hospital- and community-acquired infections. CR-hvKP has brought great challenges to global public health and is associated with significant morbidity and mortality. There are many mechanisms responsible for the evolution of the hypervirulence and carbapenem resistance phenotypes, such as the horizontal transfer of the plasmid carrying the carbapenem resistance gene to hypervirulent Klebsiella pneumoniae (hvKP) or carbapenemase-producing Klebsiella pneumoniae (CRKP) acquiring a hypervirulence plasmid carrying a virulence-encoding gene. Notably, KP can evolve into CR-hvKP by acquiring a hybrid plasmid carrying both the carbapenem resistance and hypervirulence genes. In this review, we summarize the evolutionary mechanisms of resistance and plasmid-borne virulence as well as the prevalence of CR-hvKP.Entities:
Keywords: Klebsiella pneumoniae; carbapenem-resistant; evolution; hybrid plasmid; hypervirulent
Year: 2022 PMID: 36188002 PMCID: PMC9524375 DOI: 10.3389/fmicb.2022.1003783
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 6.064
Figure 1Global distribution of CR-hvKP (2015–2022). KPC, Klebsiella pneumoniae carbapenemase; NDM, New Delhi metallo-β-lactamase; VIM, Verona integron-encoded metallo-β-lactamase; IMP, imipenemase; OXA, oxacillinase.
Global geographic distribution of isolates obtained carbapenem resistance gene from June 2015 to April 2022.
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| China | 87.3% (715/819) | 3.3% (27/819) | 1.3% (11/819) | 0.3% (3/819) | 0.2% (2/819) | 7.6% (61/819) | |
| India | 0% (0/4) | 0% (0/4) | 75.0% (3/4) | 0% (0/4) | 0% (0/4) | 25.0% (1/4) | |
| Iran | 0% (0/133) | 7.6% (10/133) | 54.9% (73/133) | 0% (0/133) | 3.7% (5/133) | 33.8% (45/133) | |
| Singapore | 90.0% (45/50) | 0% (0/50) | 0% (0/50) | 0% (0/50) | 0% (0/50) | 10.0% (5/50) | |
| Japan | 0% (0/42) | 0% (0/42) | 0% (0/42) | 100.0% (42/42) | 0% (0/42) | 0% (0/42) | |
| Russia | 0% (0/30) | 0.7% (2/30) | 70.0% (21/30) | 0% (0/30) | 0% (0/30) | 23.3% (7/30) | |
| Italy | 0% (0/5) | 0% (0/5) | 0% (0/5) | 0% (0/5) | 0% (0/5) | 100% (5/5) | |
| United Kingdom | 0% (0/17) | 58.9% (10/17) | 23.5% (4/17) | 0% (0/17) | 0% (0/17) | 17.6% (3/17) | |
| France | 0% (0/1) | 0% (0/1) | 100.0% (1/1) | 0% (0/1) | 0% (0/1) | 0% (0/1) |
|
| Germany | 56.0% (60/107) | 4.7% (5/107) | 39.3% (42/107) | 0% (0/107) | 0% (0/107) | 0% (0/107) |
|
| Portugal | 0% (0/1) | 0% (0/1) | 0% (0/1) | 0% (0/1) | 0% (0/1) | 100.0% (1/1) |
|
| United States | 60.0% (3/5) | 0.0% (0/5) | 0.0% (0/5) | 0.0% (0/5) | 0.0% (0/5) | 40.0% (2/5)` | |
| Canada | 100% (2/2) | 0% (0/2) | 0% (0/2) | 0% (0/2) | 0% (0/2) | 0% (0/2) |
|
| Colombia | 100% (1/1) | 0% (0/1) | 0% (0/1) | 0% (0/1) | 0% (0/1) | 0% (0/1) |
|
| Egypt | 0% (0/2) | 0% (0/2) | 0% (0/2) | 0% (0/2) | 0% (0/2) | 100.0% (2/2) | |
| Sudan | 0% (0/10) | 20% (2/10) | 80% (8/10) | 0% (0/10) | 0% (0/10) | 0% (0/10) |
|
| Total | 67.2% (826/1229) | 4.6% (56/1229) | 13.2% (163/1229) | 3.7% (45/1229) | 0.6% (7/1229) | 10.7% (132/1229) |
Figure 2The molecular evolution and carbapenem-resistance mechanism of CR-hvKP.